- Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its intravenous formulation
- Application seeks approval for subcutaneous nivolumab formulation to treat multiple Opdivo adult solid tumor indications in the European Union
The European Medicines Agency Has Validated The Extension Application To Introduce Subcutaneous Administration For Bristol Myers Squibb's Opdivo (Nivolumab) And A New Strength (600 Mg/Vial) Across Multiple Previously Approved Adult Solid Tumor Indications
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.